Table 2 Baseline characteristics
Trial dataset | Across I | Across III | Combined | ||||||
|---|---|---|---|---|---|---|---|---|---|
1% iCPM | Placebo | P value | 0.4% iCPM | Placebo | P value | iCPM | Placebo | P value | |
N (no of patients) | 55 | 46 | 84 | 74 | 139 | 120 | |||
Mean Age (Yrs.) | 45 | 48 | 0.37 | 55 | 51 | 0.28 | 51 | 50 | 0.727 |
Sex (M/F) | 27/28 | 25/21 | 0.59 | 38/46 | 35/39 | 0.79 | 65/74 | 60/60 | 0.603 |
Vaccination status (%) | 55 (100%) | 45 (98%) | 0.28 | 83 (99%) | 74 (100%) | 0.34 | 138 (99%) | 119 (99%) | 0.917 |
Asthma | 0 | 2 | 0.12 | 4 | 6 | 0.37 | 4 | 8 | 0.140 |
COPD | 0 | 1 | 0.28 | 4 | 1 | 0.23 | 4 | 2 | 0.525 |
Smoking History | 2 | 3 | 0.51 | 3 | 4 | 0.58 | 5 | 7 | 0.393 |
Diabetes | 6 | 5 | 0.99 | 9 | 10 | 0.57 | 15 | 15 | 0.651 |
Sleep Apnea | 0 | 1 | 0.27 | 2 | 6 | 0.10 | 2 | 7 | 0.052 |
Rhinitis | 5 | 2 | 0.35 | 8 | 6 | 0.76 | 13 | 8 | 0.430 |
Sinusitis | 0 | 0 | NA | 1 | 1 | 0.91 | 1 | 1 | 0.912 |
Nasal Polyps | 0 | 0 | NA | 0 | 1 | 0.28 | 0 | 1 | 0.279 |
AHT | 17 | 13 | 0.78 | 23 | 26 | 0.27 | 40 | 39 | 0.488 |